Antibodies to heat-shock protein 27 and breast cancer survival
Author Information
Author(s): SE Conroy, PD Sasieni, V Amin, DY Wang, P Smith, IS Fentiman, DS Latchman
Primary Institution: University College London Medical School
Hypothesis
Do antibodies to hsp27 and hsp70 correlate with clinical features or prognosis in breast cancer patients?
Conclusion
The presence of antibodies to hsp27 is associated with improved survival in breast cancer patients.
Supporting Evidence
- Antibodies to hsp27 were found in over one-third of breast cancer patients but only in one normal individual.
- Patients with antibodies to hsp27 had a lower average mortality rate compared to those without.
- The presence of antibodies to hsp70 did not show a significant difference in survival rates.
Takeaway
This study found that having antibodies to a specific protein called hsp27 can help breast cancer patients live longer.
Methodology
Sera from breast cancer patients were tested for antibodies to hsp27 and hsp70 using ELISA assays.
Limitations
The study only included patients diagnosed at one hospital and may not be generalizable.
Participant Demographics
Patients included both node-negative and node-positive women, oestrogen receptor-negative and -positive women, and pre-, peri-, and post-menopausal women.
Statistical Information
P-Value
0.006
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website